TD Cowen has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to hold from sell, stating it now sees less downside to the stock. "We believe Casgevy expectations have bottomed out in the near term and CRISPR should get some platform value,

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating comes as the firm sees reduced downside risk for the company's shares,

TD Cowen raised the firm’s price target on Confluent (CFLT) to $41 from $37 and keeps a Buy rating on the shares. The firm said they posted a

TD Cowen reiterated its Buy rating on Apollo Global Management (NYSE:APO) shares, maintaining a price target of $214.00. Currently trading at $159.29 with a market capitalization of $90.6 billion, InvestingPro analysis indicates the stock is currently undervalued based on its Fair Value model.